- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Newsletter: November 2021
Regulatory Updates
WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility Read More
WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date Read More
WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate Read More
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility Read More
WuXi Biologics Receives GMP Conformity Assessment from the Singapore Health Sciences Authority (HSA) Read More
Resources
The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution. View this Podcast
For more information on our Quality track record, please click this infographic.
Partner News
WuXi Biologics Congratulates Amicus on U.S. FDA’s Acceptance of its Filing for AT-GAA for the Treatment of Pompe Disease Read More
